These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21730282)

  • 1. Busulfan and metronidazole: an often forgotten but significant drug interaction.
    Gulbis AM; Culotta KS; Jones RB; Andersson BS
    Ann Pharmacother; 2011 Jul; 45(7-8):e39. PubMed ID: 21730282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipients.
    Le Gall JB; Milone MC; Waxman IM; Shaw LM; Harrison L; Duffy D; van de Ven C; Militano O; Geyer MB; Morris E; Bhatia M; Satwani P; George D; Garvin JH; Bradley MB; Schwartz J; Baxter-Lowe LA; Cairo MS
    Bone Marrow Transplant; 2013 Jan; 48(1):19-25. PubMed ID: 22684047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
    Saraceni F; Beohou E; Labopin M; Arcese W; Bonifazi F; Stepensky P; Aljurf M; Bruno B; Pioltelli P; Passweg J; Sociè G; Santarone S; Yakoub-Agha I; Lanza F; Savani BN; Mohty M; Nagler A;
    Am J Hematol; 2018 Oct; 93(10):1211-1219. PubMed ID: 30033639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
    McPherson ME; Hutcherson D; Olson E; Haight AE; Horan J; Chiang KY
    Bone Marrow Transplant; 2011 Jan; 46(1):27-33. PubMed ID: 20305698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
    Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel drug interaction between busulfan and blinatumomab.
    Sweiss K; Quigley JG; Oh A; Lee J; Ye R; Rondelli D; Patel P
    J Oncol Pharm Pract; 2019 Jan; 25(1):226-228. PubMed ID: 28857712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.
    Nishikawa T; Okamoto Y; Tanabe T; Shinkoda Y; Kodama Y; Higashi M; Hirano H; Arita K; Kawano Y
    Bone Marrow Transplant; 2010 Mar; 45(3):602-4. PubMed ID: 19684630
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
    Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
    Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation.
    Hilger RA; Baumgart J; Scheulen ME; Trenschel R; Strumberg D; Seeber S; Beelen DW
    Int J Clin Pharmacol Ther; 2004 Nov; 42(11):654-5. PubMed ID: 15598037
    [No Abstract]   [Full Text] [Related]  

  • 10. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
    Główka FK; Romański M; Wachowiak J
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
    Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
    Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study.
    Jansing T; Sanpakit K; Tharnpanich T; Jiranantakan T; Niphandwongkorn V; Chindavijak B; Suansanae T
    Pediatr Hematol Oncol; 2021 May; 38(4):346-357. PubMed ID: 33656974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.
    Mannis GN; Andreadis C; Logan AC; Damon LE; Benet LZ; Ai WZ; Gaensler KM; Kaplan LD; Koplowicz YB; Linker CA; Olin RL; Sayre PH; Smith CC; Sudhindra A; Venstrom JM; Wolf JL; Martin TG
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):377-83. PubMed ID: 25776193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
    Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
    Veal GJ; Nguyen L; Paci A; Riggi M; Amiel M; Valteau-Couanet D; Brock P; Ladenstein R; Vassal G
    Eur J Cancer; 2012 Nov; 48(16):3063-72. PubMed ID: 22742881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Significant Influence of Metronidazole on Busulfan Pharmacokinetics: A Case Report of Therapeutic Drug Monitoring.
    Chung H; Yu KS; Hong KT; Choi JY; Hong CR; Kang HJ; Park KD; Shin HY; Lee S
    Ther Drug Monit; 2017 Jun; 39(3):208-210. PubMed ID: 28328762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation.
    Slattery JT; Risler LJ
    Ther Drug Monit; 1998 Oct; 20(5):543-9. PubMed ID: 9780133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of busulfan in transplantation.
    Russell JA; Kangarloo SB
    Curr Pharm Des; 2008; 14(20):1936-49. PubMed ID: 18691105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan.
    Gibbs JP; Murray G; Risler L; Chien JY; Dev R; Slattery JT
    Cancer Res; 1997 Dec; 57(24):5509-16. PubMed ID: 9407960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.
    McDonald GB; Evans AT; McCune JS; Schoch G; Ostrow JD; Gooley TA
    Lancet Haematol; 2016 Nov; 3(11):e516-e525. PubMed ID: 27968820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.